Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Withdrawal-Emergent Dyskinesia Following Abrupt Discontinuation of Desvenlafaxine.

Wu L, Gerdts EA, Alam A.

Prim Care Companion CNS Disord. 2019 Jan 10;21(1). pii: 18l02362. doi: 10.4088/PCC.18l02362. No abstract available.

2.

Switch to a manic episode after desvenlafaxine discontinuation in bipolar disorder.

Muquebil Ali Al Shaban-Rodríguez OW, Álvarez de Morales E, Rodríguez-Turiel C, Fernández-Menéndez MA, García-Álvarez G.

Actas Esp Psiquiatr. 2018 Jul;46(4):156-8. Epub 2018 Jul 1. No abstract available.

3.

Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.

Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J.

Psychother Psychosom. 2018;87(4):195-203. doi: 10.1159/000491524. Epub 2018 Jul 17. Review.

4.

Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.

Weihs KL, Murphy W, Abbas R, Chiles D, England RD, Ramaker S, Wajsbrot DB.

J Child Adolesc Psychopharmacol. 2018 Feb;28(1):36-46. doi: 10.1089/cap.2017.0100. Epub 2017 Nov 30.

5.

Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder.

Atkinson S, Lubaczewski S, Ramaker S, England RD, Wajsbrot DB, Abbas R, Findling RL.

J Child Adolesc Psychopharmacol. 2018 Feb;28(1):55-65. doi: 10.1089/cap.2017.0099. Epub 2017 Nov 29.

6.

False-positive phencyclidine (PCP) on urine drug screen attributed to desvenlafaxine (Pristiq) use.

Farley TM, Anderson EN, Feller JN.

BMJ Case Rep. 2017 Nov 23;2017. pii: bcr-2017-222106. doi: 10.1136/bcr-2017-222106.

PMID:
29170178
7.

Takotsubo Cardiomyopathy and Intraoperative Cardiac Arrest: Is Desvenlafaxine a Contributing Factor?

Gurunathan U.

J Cardiothorac Vasc Anesth. 2018 Feb;32(1):e16-e18. doi: 10.1053/j.jvca.2017.08.031. Epub 2017 Aug 19. No abstract available.

PMID:
29153932
8.
9.

Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline.

Mosca D, Zhang M, Prieto R, Boucher M.

J Clin Psychopharmacol. 2017 Apr;37(2):182-192. doi: 10.1097/JCP.0000000000000674.

PMID:
28146000
10.

Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects.

Cooper JM, Brown JA, Cairns R, Isbister GK.

Clin Toxicol (Phila). 2017 Jan;55(1):18-24. doi: 10.1080/15563650.2016.1223847. Epub 2016 Sep 13.

PMID:
27622824
11.

Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder.

Findling RL, Groark J, Tourian KA, Ramaker SA, Chiles D, Yang L, Nichols AI.

J Child Adolesc Psychopharmacol. 2016 Dec;26(10):909-921. Epub 2016 Jul 18.

PMID:
27428303
12.
13.

UV/H2O2degradation of the antidepressants venlafaxine and O-desmethylvenlafaxine: Elucidation of their transformation pathway and environmental fate.

García-Galán MJ, Anfruns A, Gonzalez-Olmos R, Rodríguez-Mozaz S, Comas J.

J Hazard Mater. 2016 Jul 5;311:70-80. doi: 10.1016/j.jhazmat.2016.02.070. Epub 2016 Mar 2.

PMID:
26954478
14.

An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.

Carrasco JL, Kornstein SG, McIntyre RS, Fayyad R, Prieto R, Salas M, Mackell J, Boucher M.

Int Clin Psychopharmacol. 2016 May;31(3):134-46. doi: 10.1097/YIC.0000000000000121.

PMID:
26895080
15.

Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine.

Ghosh R, Gupta R, Bhatia MS, Tripathi AK, Gupta LK.

Asian J Psychiatr. 2015 Dec;18:37-41. doi: 10.1016/j.ajp.2015.10.006. Epub 2015 Oct 19.

PMID:
26514447
16.

Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis.

Renoux C, Lix LM, Patenaude V, Bresee LC, Paterson JM, Lafrance JP, Tamim H, Mahmud SM, Alsabbagh MW, Hemmelgarn B, Dormuth CR, Ernst P; Canadian Network of Observational Drug Effect Studies (CNODES) Investigators.

Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1716-22. doi: 10.2215/CJN.11271114. Epub 2015 Jul 31.

17.

Effects of 50 and 100 mg desvenlafaxine versus placebo on sexual function in patients with major depressive disorder: a meta-analysis.

Clayton AH, Hwang E, Kornstein SG, Tourian KA, Cheng RF, Abraham L, Mele L, Boucher M.

Int Clin Psychopharmacol. 2015 Nov;30(6):307-15. doi: 10.1097/YIC.0000000000000094.

PMID:
26230270
18.

Desvenlafaxine for the acute treatment of depression: a systematic review and meta-analysis.

Laoutidis ZG, Kioulos KT.

Pharmacopsychiatry. 2015 Sep;48(6):187-99. doi: 10.1055/s-0035-1555879. Epub 2015 Jul 23. Review.

PMID:
26205685
19.

The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.

Handley AP, Williams M.

J Am Assoc Nurse Pract. 2015 Jan;27(1):54-61. doi: 10.1002/2327-6924.12137. Epub 2014 Jun 19. Review.

PMID:
24944075

Supplemental Content

Loading ...
Support Center